Loading...

STAAR Surgical

DB:SR3
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SR3
DB
$1B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
  • STAAR Surgical has significant price volatility in the past 3 months.
SR3 Share Price and Events
7 Day Returns
-3%
DB:SR3
-2.4%
DE Medical Equipment
-2.3%
DE Market
1 Year Returns
-8.7%
DB:SR3
12.3%
DE Medical Equipment
-11.5%
DE Market
SR3 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
STAAR Surgical (SR3) -3% -23.1% -33.8% -8.7% 347.8% 91.2%
DE Medical Equipment -2.4% -1.3% 5% 12.3% 99.5% 227%
DE Market -2.3% -5.2% 0.8% -11.5% 5.6% 6.4%
1 Year Return vs Industry and Market
  • SR3 underperformed the Medical Equipment industry which returned 12.3% over the past year.
  • SR3 outperformed the Market in Germany which returned -11.5% over the past year.
Price Volatility
SR3
Industry
5yr Volatility vs Market

Value

 Is STAAR Surgical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of STAAR Surgical to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for STAAR Surgical.

DB:SR3 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:SR3
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.89
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.894 (1 + (1- 21%) (1.08%))
0.934
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.93
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.934 * 5.96%)
5.79%

Discounted Cash Flow Calculation for DB:SR3 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for STAAR Surgical is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:SR3 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.79%)
2019 -0.81 Analyst x1 -0.77
2020 14.17 Analyst x1 12.66
2021 40.14 Analyst x1 33.90
2022 62.59 Est @ 55.95% 49.97
2023 87.15 Est @ 39.23% 65.76
2024 111.15 Est @ 27.53% 79.28
2025 132.64 Est @ 19.34% 89.43
2026 150.69 Est @ 13.61% 96.03
2027 165.15 Est @ 9.59% 99.48
2028 176.35 Est @ 6.78% 100.41
Present value of next 10 years cash flows $626.16
DB:SR3 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $176.35 × (1 + 0.23%) ÷ (5.79% – 0.23%)
$3,175.96
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $3,175.96 ÷ (1 + 5.79%)10
$1,808.39
DB:SR3 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $626.16 + $1,808.39
$2,434.55
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,434.55 / 44.47
$54.74
DB:SR3 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:SR3 represents 0.86675x of NasdaqGM:STAA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86675x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 54.74 x 0.86675
€47.45
Value per share (EUR) From above. €47.45
Current discount Discount to share price of €21.40
= -1 x (€21.40 - €47.45) / €47.45
54.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price STAAR Surgical is available for.
Intrinsic value
>50%
Share price is €21.4 vs Future cash flow value of €47.45
Current Discount Checks
For STAAR Surgical to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • STAAR Surgical's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • STAAR Surgical's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for STAAR Surgical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are STAAR Surgical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:SR3 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-29) in USD $0.13
NasdaqGM:STAA Share Price ** NasdaqGM (2019-05-24) in USD $24.69
Germany Medical Equipment Industry PE Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 35.2x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 20.16x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of STAAR Surgical.

DB:SR3 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:STAA Share Price ÷ EPS (both in USD)

= 24.69 ÷ 0.13

185.83x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • STAAR Surgical is overvalued based on earnings compared to the DE Medical Equipment industry average.
  • STAAR Surgical is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does STAAR Surgical's expected growth come at a high price?
Raw Data
DB:SR3 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 185.83x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
70.9%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 3x
Germany Market PEG Ratio Median Figure of 271 Publicly-Listed Companies 1.48x

*Line of best fit is calculated by linear regression .

DB:SR3 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 185.83x ÷ 70.9%

2.62x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • STAAR Surgical is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on STAAR Surgical's assets?
Raw Data
DB:SR3 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-29) in USD $3.09
NasdaqGM:STAA Share Price * NasdaqGM (2019-05-24) in USD $24.69
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.12x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.75x
DB:SR3 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:STAA Share Price ÷ Book Value per Share (both in USD)

= 24.69 ÷ 3.09

7.99x

* Primary Listing of STAAR Surgical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • STAAR Surgical is overvalued based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess STAAR Surgical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. STAAR Surgical has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is STAAR Surgical expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
70.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is STAAR Surgical expected to grow at an attractive rate?
  • STAAR Surgical's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • STAAR Surgical's earnings growth is expected to exceed the Germany market average.
  • STAAR Surgical's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:SR3 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:SR3 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 70.9%
DB:SR3 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 21%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 12.6%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.2%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:SR3 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:SR3 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 228 44 34 3
2020-12-31 182 21 17 5
2019-12-31 151 4 8 5
DB:SR3 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-29 129 11 6
2018-12-28 124 13 5
2018-09-28 118 12 4
2018-06-29 109 7 3
2018-03-30 97 6 1
2017-12-29 91 3 -2
2017-09-29 88 2 -2
2017-06-30 84 0 -5
2017-03-31 84 3 -6
2016-12-30 82 1 -12
2016-09-30 81 -1 -13
2016-07-01 80 -1 -13
2016-04-01 78 -3 -12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • STAAR Surgical's earnings are expected to grow significantly at over 20% yearly.
  • STAAR Surgical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:SR3 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from STAAR Surgical Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:SR3 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.72 0.88 0.47 3.00
2020-12-31 0.37 0.50 0.17 4.00
2019-12-31 0.17 0.21 0.14 4.00
DB:SR3 Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-29 0.13
2018-12-28 0.12
2018-09-28 0.09
2018-06-29 0.08
2018-03-30 0.02
2017-12-29 -0.05
2017-09-29 -0.05
2017-06-30 -0.13
2017-03-31 -0.16
2016-12-30 -0.30
2016-09-30 -0.32
2016-07-01 -0.32
2016-04-01 -0.31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • STAAR Surgical is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess STAAR Surgical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
STAAR Surgical has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has STAAR Surgical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare STAAR Surgical's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • STAAR Surgical has delivered over 20% year on year earnings growth in the past 5 years.
  • STAAR Surgical's 1-year earnings growth exceeds its 5-year average (833.2% vs 35.9%)
  • STAAR Surgical's earnings growth has exceeded the DE Medical Equipment industry average in the past year (833.2% vs 3.2%).
Earnings and Revenue History
STAAR Surgical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from STAAR Surgical Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:SR3 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-29 129.44 5.75 66.69 22.26
2018-12-28 123.95 4.97 62.93 22.03
2018-09-28 117.62 3.73 60.77 21.02
2018-06-29 109.32 3.45 55.26 20.05
2018-03-30 97.35 0.65 50.51 19.38
2017-12-29 90.61 -2.14 47.79 20.04
2017-09-29 87.90 -2.17 45.20 18.69
2017-06-30 84.48 -5.12 46.12 18.55
2017-03-31 83.51 -6.29 46.47 18.17
2016-12-30 82.43 -12.13 50.26 20.67
2016-09-30 81.15 -12.81 51.15 19.98
2016-07-01 79.85 -12.78 50.15 19.21
2016-04-01 77.53 -12.23 48.61 18.09
2016-01-01 77.12 -6.53 43.30 14.76
2015-10-02 72.71 -8.23 42.45 14.05
2015-07-03 72.15 -9.18 41.59 13.50
2015-04-03 73.58 -9.37 43.29 12.46
2015-01-02 74.99 -8.39 44.17 12.36
2014-10-03 77.30 -6.73 46.22 11.09
2014-07-04 76.18 -3.50 45.60 9.64
2014-04-04 74.21 -1.43 42.91 8.83
2014-01-03 72.01 0.40 40.66 6.71
2013-09-27 69.59 -0.14 38.45 6.54
2013-06-28 68.39 -0.76 37.74 6.44
2013-03-29 66.22 -1.52 36.60 6.26
2012-12-28 63.78 -1.76 36.43 6.44
2012-09-28 63.70 -0.24 34.59 6.23
2012-06-29 63.10 -0.07 33.89 6.10

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • STAAR Surgical has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • STAAR Surgical used its assets less efficiently than the DE Medical Equipment industry average last year based on Return on Assets.
  • STAAR Surgical has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess STAAR Surgical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
STAAR Surgical has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is STAAR Surgical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up STAAR Surgical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • STAAR Surgical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • STAAR Surgical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of STAAR Surgical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 12.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from STAAR Surgical Company Filings, last reported 1 month ago.

DB:SR3 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-29 137.34 11.85 102.11
2018-12-28 132.43 5.34 103.88
2018-09-28 128.86 6.18 102.20
2018-06-29 51.08 6.98 21.25
2018-03-30 45.92 7.76 20.77
2017-12-29 42.94 6.25 18.52
2017-09-29 40.66 6.55 16.13
2017-06-30 38.29 6.84 13.44
2017-03-31 36.96 7.19 13.50
2016-12-30 37.91 6.82 14.00
2016-09-30 37.73 7.02 14.28
2016-07-01 37.99 6.60 12.69
2016-04-01 38.33 4.94 8.97
2016-01-01 38.85 4.73 13.40
2015-10-02 39.54 4.73 16.08
2015-07-03 39.79 4.71 15.34
2015-04-03 36.35 4.93 10.81
2015-01-02 37.10 5.02 13.01
2014-10-03 40.64 5.56 18.36
2014-07-04 41.83 5.97 19.19
2014-04-04 41.26 5.18 21.07
2014-01-03 38.85 5.18 22.95
2013-09-27 37.82 5.65 23.35
2013-06-28 34.66 5.90 19.73
2013-03-29 32.65 6.35 19.24
2012-12-28 31.74 7.17 21.68
2012-09-28 32.62 4.05 19.75
2012-06-29 31.49 4.10 17.54
  • STAAR Surgical's level of debt (8.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (12.6% vs 8.6% today).
  • Debt is well covered by operating cash flow (92.5%, greater than 20% of total debt).
  • STAAR Surgical earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess STAAR Surgical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. STAAR Surgical has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is STAAR Surgical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from STAAR Surgical dividends.
If you bought €2,000 of STAAR Surgical shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate STAAR Surgical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate STAAR Surgical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:SR3 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:SR3 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as STAAR Surgical has not reported any payouts.
  • Unable to verify if STAAR Surgical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of STAAR Surgical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as STAAR Surgical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess STAAR Surgical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can STAAR Surgical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. STAAR Surgical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of STAAR Surgical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Caren Mason
COMPENSATION $2,627,201
AGE 64
TENURE AS CEO 4.2 years
CEO Bio

Ms. Caren L. Mason has been the Chief Executive Officer and President of STAAR Surgical Company since March 1, 2015. Ms. Mason served as the Chief Executive Officer of Verinata Health, Inc. from April 2011 to 2012. She served as the Chief Executive Officer and President of Quidel Corporation from August 20, 2004 to March 1, 2009. Ms. Mason served as Chief Executive Officer of Merge Healthcare North America since January 17, 2000. She served as Chief Executive Officer and President of MiraMedica Inc. from 2002 to 2003, an entrepreneurial, pioneering digital technology, diagnostic imaging company. She started her career with Baxter/American Hospital Supply, moving rapidly through the sales and marketing ranks before moving on to Bayer AG, where she assumed the position of Senior Vice President of AGFA Technical Imaging Systems business group, after achieving notable success in National Accounts, Marketing and Business Development. Most recently, after selling MiraMedica to Eastman Kodak, Ms. Mason provided transition support and consultative services to Kodak in Women's Health. She first joined AGFA Technical Imaging Systems business group in 1989 and held various management positions prior to her assignment as Senior Vice President. Ms. Mason provided consultative services from 2003 to 2004 for Eastman Kodak Health Imaging at MiraMedica, Inc. Ms. Mason served as the Chief Executive Officer of eMed Technologies of Lexington. She served as a Special Advisor of Quidel Corporation from March 1, 2009 to June 1, 2009. She was then recruited to GE Medical Systems, where she was quickly promoted to lead several re-positioning general management assignments. From 1996 to 1999, Ms. Mason held various senior management positions at General Electric, with her most recent position as that of General Manager of Womens Healthcare Business and as a General Manager in various capacities for the Services business of General Electric Healthcare from 1996 to 2000. Prior to her work with General Electric, Ms. Mason’s additional healthcare experience includes her tenure with Bayer AG/AGFA from 1989 to 1996 where she last held the positions of Senior Vice President for Bayer Corporate Health Care and Senior Vice President for the AGFA Technical Imaging Business Group. Ms. Mason began her career in healthcare with American Hospital Supply/Baxter Healthcare in sales, marketing and managerial roles from 1977 through 1988. She has more than 30 years of commercial and diagnostic healthcare experience. She has more than 25 years experience in healthcare. She has been a Director of HealthTell, Inc since December 2014. She served as a Director of Verinata Health, Inc since April 2011. She has been Member of Strategic Advisory Board at InDevR, Inc since September 30, 2015. She serves as a Director of MediServ/GESCI, UCSD Moores Cancer Center, AdvaMed, eMed Technologies Inc., and MiraMedica Inc. She serves as the boards of the Partners for Philanthropic Change, Alliance for Global Good. Ms. Mason served as a Director of Quidel Corporation from August 20, 2004 to 2009. She has extensive executive education, including that from the University of Chicago, Round Table Group and GE Crotonville. She has been a Director of STAAR Surgical Company since June 2014. She has been a member of the Franciscan Sisters of the Poor Foundation Board of Governors, winning their Heritage Award in 1995. Ms. Mason studied B.A. of Indiana University.

CEO Compensation
  • Caren's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Caren's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the STAAR Surgical management team in years:

2.2
Average Tenure
59
Average Age
  • The tenure for the STAAR Surgical management team is about average.
Management Team

Caren Mason

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
64
TENURE
4.2 yrs

Deborah Andrews

TITLE
Chief Financial Officer
COMPENSATION
$823K
AGE
61
TENURE
1.7 yrs

Keith Holliday

TITLE
Chief Technology Officer
COMPENSATION
$1M
AGE
55
TENURE
2.2 yrs

Sam Gesten

TITLE
Chief Legal Officer & Corporate Secretary
COMPENSATION
$989K
AGE
56
TENURE
2.1 yrs

Hans-Martin Blickensdoerfer

TITLE
Senior VP of Commercial Operations
COMPENSATION
$1M
AGE
53
TENURE
2.5 yrs

Graydon Hansen

TITLE
Senior Vice President of Global Operations
AGE
59
TENURE
1.5 yrs

Brian Moore

TITLE
Sr. Director of Investor

Bill Goodmen

TITLE
Vice President of Global Human Resources
AGE
63
TENURE
8.8 yrs

James Francese

TITLE
Senior Vice President of Commercial Operations - North America & APAC
COMPENSATION
$578K
AGE
54
TENURE
1.5 yrs

Denise McEachern

TITLE
Global Head of Regulatory Affairs & Quality Assurance
AGE
59
TENURE
4.4 yrs
Board of Directors Tenure

Average tenure and age of the STAAR Surgical board of directors in years:

4.3
Average Tenure
59
Average Age
  • The tenure for the STAAR Surgical board of directors is about average.
Board of Directors

Lou Silverman

TITLE
Chairman
COMPENSATION
$212K
AGE
59
TENURE
2.9 yrs

Caren Mason

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
64
TENURE
4.9 yrs

William Wall

TITLE
Director
COMPENSATION
$200K
AGE
56
TENURE
3.7 yrs

Steve Farrell

TITLE
Director
COMPENSATION
$187K
AGE
53
TENURE
3.3 yrs

John Moore

TITLE
Independent Director
COMPENSATION
$177K
AGE
74
TENURE
11.3 yrs

Brian Williams

TITLE
Member of Optometric Advisory Council
TENURE
10.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
03. May 19 Buy Broadwood Capital, Inc. Company 03. May 19 03. May 19 100,000 €19.86 €1,986,028
20. Aug 18 Sell William Wall Individual 20. Aug 18 20. Aug 18 -5,000 €36.16 €-180,782
X
Management checks
We assess STAAR Surgical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. STAAR Surgical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers intraocular lenses (IOLs), including collamer material and silicone foldable IOLs, and nanoFLEX IOL that produces a clearer image, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision centers, surgical centers, hospitals, government facilities, and distributors primarily under the STAAR, EVO Visian ICL, Evolution in Visual Freedom, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, and Afinity trademarks. The company sells products directly through its sales representatives in the United States, Japan, Spain, Germany, Canada, the United Kingdom, and Singapore, as well as through independent distributors in China, Korea, India, and internationally. STAAR Surgical Company was founded in 1982 and is based in Monrovia, California.

Details
Name: STAAR Surgical Company
SR3
Exchange: DB
Founded: 1982
$979,666,441
44,472,846
Website: http://www.staar.com
Address: STAAR Surgical Company
1911 Walker Avenue,
Monrovia,
California, 91016,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM STAA Common Stock Nasdaq Global Market US USD 07. Jul 1983
DB SR3 Common Stock Deutsche Boerse AG DE EUR 07. Jul 1983
Number of employees
Current staff
Staff numbers
475
STAAR Surgical employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/25 21:32
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2019/05/06
Last earnings filing: 2019/05/01
Last earnings reported: 2019/03/29
Last annual earnings reported: 2018/12/28


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.